OA11677A - Pharmaceutical composition for modified release ofan insulin sensitiser and another antidiabetic agent. - Google Patents

Pharmaceutical composition for modified release ofan insulin sensitiser and another antidiabetic agent. Download PDF

Info

Publication number
OA11677A
OA11677A OA1200100117A OA1200100117A OA11677A OA 11677 A OA11677 A OA 11677A OA 1200100117 A OA1200100117 A OA 1200100117A OA 1200100117 A OA1200100117 A OA 1200100117A OA 11677 A OA11677 A OA 11677A
Authority
OA
OAPI
Prior art keywords
composition according
tablet
release
composition
insulin
Prior art date
Application number
OA1200100117A
Other languages
English (en)
Inventor
Karen Lewis
Nicola Jayne Lilliott
Donald Colin Mackenzie
Vincenzo Re
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547326&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11677(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9824867.7A external-priority patent/GB9824867D0/en
Priority claimed from GBGB9824869.3A external-priority patent/GB9824869D0/en
Priority claimed from GBGB9824866.9A external-priority patent/GB9824866D0/en
Priority claimed from GBGB9912190.7A external-priority patent/GB9912190D0/en
Priority claimed from GBGB9912191.5A external-priority patent/GB9912191D0/en
Priority claimed from GBGB9912193.1A external-priority patent/GB9912193D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA11677A publication Critical patent/OA11677A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
OA1200100117A 1998-11-12 1999-11-08 Pharmaceutical composition for modified release ofan insulin sensitiser and another antidiabetic agent. OA11677A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9824867.7A GB9824867D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9824869.3A GB9824869D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9824866.9A GB9824866D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912190.7A GB9912190D0 (en) 1999-05-25 1999-05-25 Novel composition and use
GBGB9912191.5A GB9912191D0 (en) 1999-05-25 1999-05-25 Novel composition and use
GBGB9912193.1A GB9912193D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Publications (1)

Publication Number Publication Date
OA11677A true OA11677A (en) 2005-01-12

Family

ID=27547326

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100117A OA11677A (en) 1998-11-12 1999-11-08 Pharmaceutical composition for modified release ofan insulin sensitiser and another antidiabetic agent.

Country Status (36)

Country Link
EP (3) EP1131070B1 (zh)
JP (1) JP2002529504A (zh)
KR (1) KR100643833B1 (zh)
CN (1) CN1230162C (zh)
AR (1) AR024228A1 (zh)
AT (1) ATE406889T1 (zh)
AU (1) AU768994B2 (zh)
BG (2) BG109852A (zh)
BR (1) BR9915285A (zh)
CA (1) CA2351058A1 (zh)
CY (1) CY1108587T1 (zh)
CZ (1) CZ20011629A3 (zh)
DE (1) DE69939485D1 (zh)
DK (1) DK1131070T3 (zh)
DZ (1) DZ2936A1 (zh)
EA (2) EA007610B1 (zh)
ES (1) ES2312221T3 (zh)
HK (1) HK1040910B (zh)
HR (1) HRP20010343B1 (zh)
HU (1) HUP0104303A3 (zh)
ID (1) ID28783A (zh)
IL (2) IL143002A0 (zh)
MY (1) MY124695A (zh)
NO (1) NO20012303L (zh)
NZ (1) NZ511614A (zh)
OA (1) OA11677A (zh)
PE (1) PE20001238A1 (zh)
PL (1) PL347634A1 (zh)
PT (1) PT1131070E (zh)
SI (1) SI1131070T1 (zh)
SK (1) SK287038B6 (zh)
TR (1) TR200101333T2 (zh)
TW (2) TWI251487B (zh)
UY (1) UY25799A1 (zh)
WO (1) WO2000028989A1 (zh)
YU (1) YU37301A (zh)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
SG149676A1 (en) * 1999-12-23 2009-02-27 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
AU2007201729B2 (en) * 1999-12-23 2010-02-25 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
US8257744B2 (en) * 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
WO2002036100A1 (en) * 2000-11-03 2002-05-10 Andrx Corporation Controlled release metformin compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
EP1372614A4 (en) * 2001-03-16 2007-10-31 Andrx Pharmaceuticals Llc SULPHONYL UREA FORMULATION WITH CONTROLLED RELEASE
FR2822069B1 (fr) * 2001-03-19 2003-06-20 Lipha Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete
EP1392250A2 (en) * 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
EP1429740A4 (en) * 2001-07-10 2005-01-26 Kos Life Sciences Inc CORE FORMULATION WITH TROGLITAZONE AND A BIGUANIDE
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
AU2003210477A1 (en) 2002-01-09 2003-07-30 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
EP1515701B1 (en) * 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
CA2514879C (en) * 2003-01-03 2014-09-16 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
CA2514539C (en) 2003-01-29 2012-03-06 Takeda Pharmaceutical Company Limited Process for producing coated preparation
TW200517127A (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
WO2005041962A1 (en) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
JP2007534704A (ja) * 2004-04-29 2007-11-29 美時化学製薬股▲ふん▼有限公司 経口徐放性錠剤組成物およびその製造方法
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
KR100657785B1 (ko) * 2005-02-19 2007-04-16 한국유나이티드제약 주식회사 글리메피리드, 메트포르민 및 은행엽엑스를 함유하는 약학적 조성물
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
MXPA05010977A (es) * 2005-10-12 2007-04-11 Abdala Leopoldo Espinosa Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
MXPA05014092A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
UA91729C2 (ru) 2005-12-22 2010-08-25 Такеда Фармасьютикал Компани Лимитед Твердая форма лекарственного препарата
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
CA2673111A1 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
EP2144599B1 (en) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
WO2009017383A2 (en) * 2007-08-02 2009-02-05 Handok Pharmaceuticals Co., Ltd. Sustained-release formulation comprising metformin acid salt
JP5596545B2 (ja) 2007-09-10 2014-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｓｇｌｔの阻害物質として有用な化合物の製造方法
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
CN101548961B (zh) * 2008-04-03 2011-05-04 单宝华 一种治疗糖尿病及肥胖症的口服胶囊制剂
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US9174971B2 (en) 2009-10-14 2015-11-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
TWI541030B (zh) * 2010-07-06 2016-07-11 健生藥品公司 用於糖尿病協同治療之調配物
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
WO2013103384A1 (en) * 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
BR112014016810A8 (pt) * 2012-01-06 2017-07-04 Elcelyx Therapeutics Inc composições e métodos para tratamento de distúrbios metabólicos
CN102631332A (zh) * 2012-04-28 2012-08-15 邹立兴 一种伏格列波糖片剂及其制备方法
KR101409330B1 (ko) * 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
EP2958548A1 (en) * 2013-02-19 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A production process for gliclazide formulations
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
US4538469A (en) * 1983-07-29 1985-09-03 Panametrics, Inc. Integrated threshold arming method and apparatus
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
SG59988A1 (en) 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JP2630016B2 (ja) * 1990-05-21 1997-07-16 ヤマハ株式会社 吹奏感付加器を有する電子管楽器
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
AU650465B2 (en) 1990-07-03 1994-06-23 Yamanouchi Pharmaceutical Co., Ltd. Bisheterocyclic compound
DE69106714T2 (de) 1990-08-23 1995-05-11 Pfizer Hypoglykämische hydroxyharnstoffderivate.
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
SK109993A3 (en) 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (zh) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
AU3959193A (en) 1992-04-10 1993-11-18 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type II-diabetes
WO1993022445A1 (en) 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
PL176885B1 (pl) 1992-07-03 1999-08-31 Smithkline Beecham Plc Kompozycja farmaceutyczna
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
RU2071783C1 (ru) * 1993-09-07 1997-01-20 Ессентукский центральный военный санаторий Способ получения средства для лечения сахарного диабета
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
RU2114617C1 (ru) * 1996-09-27 1998-07-10 Юрий Георгиевич Каминский Антидиабетическое средство на основе янтарной кислоты
IL132032A0 (en) * 1997-03-24 2001-03-19 Galderma Res & Dev Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment

Also Published As

Publication number Publication date
DE69939485D1 (de) 2008-10-16
SK6442001A3 (en) 2001-12-03
SI1131070T1 (sl) 2008-12-31
UY25799A1 (es) 2000-12-29
PT1131070E (pt) 2008-11-19
EP1992337A1 (en) 2008-11-19
ID28783A (id) 2001-07-05
ES2312221T3 (es) 2009-02-16
BG65351B1 (bg) 2008-03-31
MY124695A (en) 2006-06-30
BG109852A (bg) 2008-11-28
CN1230162C (zh) 2005-12-07
EP1813273A1 (en) 2007-08-01
IL143002A (en) 2007-02-11
TWI251487B (en) 2006-03-21
HK1040910A1 (en) 2002-06-28
HUP0104303A3 (en) 2003-12-29
NZ511614A (en) 2003-12-19
NO20012303D0 (no) 2001-05-10
EA011633B1 (ru) 2009-04-28
TR200101333T2 (tr) 2001-10-22
SK287038B6 (sk) 2009-10-07
TW592694B (en) 2004-06-21
NO20012303L (no) 2001-07-04
AU768994B2 (en) 2004-01-15
CY1108587T1 (el) 2014-04-09
EP1131070B1 (en) 2008-09-03
HK1040910B (zh) 2009-06-26
KR20010080419A (ko) 2001-08-22
BG105568A (en) 2002-01-31
CN1348369A (zh) 2002-05-08
KR100643833B1 (ko) 2006-11-10
PL347634A1 (en) 2002-04-22
EA200601145A1 (ru) 2009-04-28
IL143002A0 (en) 2002-04-21
DK1131070T3 (da) 2008-11-17
EA007610B1 (ru) 2006-12-29
PE20001238A1 (es) 2001-01-11
JP2002529504A (ja) 2002-09-10
EP1131070A1 (en) 2001-09-12
TW200418453A (en) 2004-10-01
AU3033800A (en) 2000-06-05
HUP0104303A2 (hu) 2002-03-28
YU37301A (sh) 2005-06-10
ATE406889T1 (de) 2008-09-15
AR024228A1 (es) 2002-09-25
CZ20011629A3 (cs) 2001-12-12
DZ2936A1 (fr) 2004-03-15
EA200100541A1 (ru) 2001-10-22
HRP20010343B1 (en) 2010-11-30
BR9915285A (pt) 2001-08-07
WO2000028989A1 (en) 2000-05-25
HRP20010343A2 (en) 2002-06-30
CA2351058A1 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
OA11677A (en) Pharmaceutical composition for modified release ofan insulin sensitiser and another antidiabetic agent.
US20080014266A1 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EP1231918B1 (en) Novel composition based on a thiazolidinedione and metformin and use
US20070281023A1 (en) Pharmaceutical composition for modified release insulin sensitiser
KR100732599B1 (ko) 조절 방출형 인슐린 감작제용 제약 조성물
OA11279A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide.
AU2757202A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AU2008203540A1 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
ZA200103843B (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
AU2005200704A1 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
UA73927C2 (en) Pharmaceutical composition of thiasolidindion and metformin providing for pulsating or delayed release for one of ingredients
ZA200203865B (en) Novel composition and use.